Design and synthesis of BPR1K653 derivatives targeting the back pocket of Aurora kinases for selective isoform inhibition
作者:Yi-Yu Ke、Chun-Ping Chang、Wen-Hsing Lin、Chia-Hua Tsai、I-Chen Chiu、Wan-Ping Wang、Pei-Chen Wang、Pei-Yi Chen、Wen-Hsin Lin、Chun-Feng Chang、Po-Chu Kuo、Jen-Shin Song、Chuan Shih、Hsing-Pang Hsieh、Ya-Hui Chi
DOI:10.1016/j.ejmech.2018.03.064
日期:2018.5
phenylurea, and showed equal or better inhibition activity for Aurora-B over Aurora-A. Conversely, preferential Aurora-A inhibition activity was observed when the same functional group was moved to the meta position of the phenylurea. Compounds 3m and 3n, both of which harbor a tertiary amino group at the meta position of the phenylurea, showed 10–16 fold inhibition selectivity for Aurora-A over Aurora-B. The
先前报道的Aurora激酶抑制剂BPR1K653的二十五种新型化学类似物(1-(4-(2-((5-氯-6-苯基呋喃[2,3 - d ]嘧啶-4-基)氨基)乙基)苯基) -3-(2-(((二甲基氨基)甲基)苯基)脲已通过Aurora-A和Aurora-B酶促激酶活性测定法进行设计,合成和评估。与BPR1K653类似,类似物3b - 3h在苯基脲的邻位具有烷基或叔氨基,并且显示出与Aurora-A相同或更好的对Aurora-B的抑制活性。相反,当相同的官能团移至苯基脲的间位时,观察到优先的Aurora-A抑制活性。化合物3m和3n,这两个都在苯基脲的间位上带有一个叔氨基,对Aurora-A的抑制选择性比Aurora-B的抑制选择性高10-16倍。在体外通过Western印迹分析激酶抑制结果进行验证,并且表明,化合物3M和3N在HCT116结肠癌细胞中,与Aurora-B(Thr232)相比,在